NO20082112L - 3-Amino-2-arylpropylazaindoler og deres anvendelse - Google Patents

3-Amino-2-arylpropylazaindoler og deres anvendelse

Info

Publication number
NO20082112L
NO20082112L NO20082112A NO20082112A NO20082112L NO 20082112 L NO20082112 L NO 20082112L NO 20082112 A NO20082112 A NO 20082112A NO 20082112 A NO20082112 A NO 20082112A NO 20082112 L NO20082112 L NO 20082112L
Authority
NO
Norway
Prior art keywords
compounds
arylpropylazaindoles
amino
methods
prodrugs
Prior art date
Application number
NO20082112A
Other languages
English (en)
Norwegian (no)
Inventor
Saul Jaime-Figueroa
Robert Greenhouse
Robert James Weikert
Lubica Raptova
Karin Ann Stein
Stephen M Lynch
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20082112L publication Critical patent/NO20082112L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
NO20082112A 2005-11-30 2008-05-06 3-Amino-2-arylpropylazaindoler og deres anvendelse NO20082112L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74127205P 2005-11-30 2005-11-30
PCT/EP2006/068650 WO2007062998A1 (en) 2005-11-30 2006-11-20 3-amino-2-arylpropyl azaindoles and uses thereof

Publications (1)

Publication Number Publication Date
NO20082112L true NO20082112L (no) 2008-06-23

Family

ID=37667384

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082112A NO20082112L (no) 2005-11-30 2008-05-06 3-Amino-2-arylpropylazaindoler og deres anvendelse

Country Status (17)

Country Link
US (2) US7638517B2 (pt)
EP (1) EP1957488B1 (pt)
JP (1) JP2009517432A (pt)
KR (1) KR101026570B1 (pt)
CN (1) CN101321752A (pt)
AR (1) AR057188A1 (pt)
AT (1) ATE442368T1 (pt)
AU (1) AU2006319233B9 (pt)
BR (1) BRPI0619184A2 (pt)
CA (1) CA2632284A1 (pt)
DE (1) DE602006009138D1 (pt)
ES (1) ES2329413T3 (pt)
NO (1) NO20082112L (pt)
RU (1) RU2008120141A (pt)
TW (1) TW200804376A (pt)
WO (1) WO2007062998A1 (pt)
ZA (1) ZA200804299B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2912744B1 (fr) * 2007-02-16 2012-09-07 Centre Nat Rech Scient Composes pyrrolo°2,3-b!pyridine,composes azaindoles utiles dans la synthese de ces composes pyrrolo°2,3-b!pyridine, leurs procedes de fabrication et leurs utilisations.
US7871802B2 (en) * 2007-10-31 2011-01-18 E.I. Du Pont De Nemours And Company Process for enzymatically converting glycolonitrile to glycolic acid
US8101642B2 (en) 2008-06-05 2012-01-24 Sk Biopharmaceuticals Co., Ltd. 3-substituted propanamine compounds
CN102026988B (zh) * 2008-06-05 2013-07-03 爱思开生物制药株式会社 3-取代的丙胺化合物
JP2012509342A (ja) 2008-11-20 2012-04-19 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換ピロロ[2,3−b]−ピリジンおよび−ピラジン
US8222416B2 (en) 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
US20130072495A1 (en) * 2010-05-14 2013-03-21 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
US20140088114A1 (en) 2011-05-16 2014-03-27 OSI Pharmaceuticals ,LLC Fused bicyclic kinase inhibitors
AR098436A1 (es) * 2013-11-19 2016-05-26 Actelion Pharmaceuticals Ltd Compuestos tricíclicos de piperidina
CN108034283B (zh) * 2017-12-15 2020-10-13 淮海工学院 一种聚乙二醇化苯并吲哚七甲川菁染料及其制备方法和应用
US20220098210A1 (en) * 2019-01-29 2022-03-31 Arizona Board Of Regents On Behalf Of The University Of Arizona Quindoline compounds and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB705652A (en) 1948-10-01 1954-03-17 Farbewerke Hoechst Ag Manufacture of 3-aminopropane compounds
DE849108C (de) 1948-10-01 1952-09-11 Hoechst Ag Verfahren zur Herstellung von 1-disubstituierten 3-Aminopropanen
NL82464C (pt) * 1952-01-05
US2708197A (en) * 1952-05-24 1955-05-10 Upjohn Co Preparation of (hydroxy-3-indole)-alkylamines
US2984670A (en) * 1959-05-22 1961-05-16 Upjohn Co Novel 3-(1-hydroxy-1-phenyl-3-aminopropyl) indoles
GB992731A (en) 1962-09-28 1965-05-19 Koninklijke Pharma Fab Nv Aminoalkyl-indolyl-benzyl alcohols
US4616080A (en) 1984-07-02 1986-10-07 Eli Lilly And Company Simplified process of forming crystalline ceftazidime pentahydrate
KR880007433A (ko) * 1986-12-22 1988-08-27 메리 앤 터커 3-아릴옥시-3-치환된 프로판아민
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
EP0424525B1 (en) * 1987-12-11 1994-12-21 Mitsui Petrochemical Industries, Ltd. Novel amines and their use
JPH0314562A (ja) 1988-04-11 1991-01-23 Nippon Chemiphar Co Ltd 新規なアルキレンジアミン誘導体およびグルタミン酸遮断剤
US4902710A (en) * 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
FR2674522B1 (fr) 1991-03-26 1993-07-16 Lipha Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant.
US5177088A (en) 1991-04-17 1993-01-05 Hoechst-Roussel Pharmaceuticals Incorporated Substituted 3-(pyridinylamino)-indoles
US5185350A (en) 1991-09-23 1993-02-09 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino-1h-indoles,1h-indazoles,2h-indazoles, benzo (b)thiophenes and 1,2-benzisothiazoles
EP0600830A1 (de) 1992-11-27 1994-06-08 Ciba-Geigy Ag Substituierte Derivate von Diaminophthalimid als Protein-Tyrosin-Kinase-Hemmer
GB9225141D0 (en) 1992-12-01 1993-01-20 Smithkline Beecham Corp Chemical compounds
GB9518552D0 (en) 1995-09-11 1995-11-08 Fujisawa Pharmaceutical Co New heterocyclic compounds
GB9523948D0 (en) 1995-11-23 1996-01-24 Univ East Anglia Process for preparing n-benzyl indoles
JPH09176162A (ja) 1995-12-22 1997-07-08 Toubishi Yakuhin Kogyo Kk チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物
US6686353B1 (en) 1996-05-20 2004-02-03 Teijin Intellectual Property Center Limited Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists
JP2002511835A (ja) 1996-06-07 2002-04-16 エヌピーエス・ファーマシウティカルズ・インコーポレイテッド 神経障害および神経病の治療に有用な受容体作動性カルシウムチャネル上の新規部位で活性な化合物
SE9701144D0 (sv) 1997-03-27 1997-03-27 Pharmacia & Upjohn Ab Novel compounds, their use and preparation
EP0887348A1 (en) 1997-06-25 1998-12-30 Boehringer Mannheim Italia S.p.A. Bis-Indole derivatives having antimetastatic activity, a process for their preparation and pharmaceutical compositions containing them
CA2303830A1 (en) 1997-09-26 1999-04-08 Merck & Co., Inc. Novel angiogenesis inhibitors
AU1124399A (en) 1997-10-28 1999-05-17 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
CA2308069A1 (en) 1997-10-28 1999-05-06 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
FR2780890B3 (fr) 1998-07-10 2000-09-01 Sanofi Sa Utilisation d'une composition pharmaceutique contenant, en association, un antagoniste des recepteurs at1 de l'angiotensine ii et l'indomethacine pour le traitement des glomerulonephrites chroniques
DE69935331T2 (de) 1998-07-13 2007-10-31 NPS Pharmaceuticals, Inc., Salt Lake City Verfahren und verbindungen zur behandlung der depression
SE9903998D0 (sv) 1999-11-03 1999-11-03 Astra Ab New compounds
FR2814073B1 (fr) 2000-09-21 2005-06-24 Yang Ji Chemical Company Ltd Composition pharmaceutique antifongique et/ou antiparasitaire et nouveaux derives de l'indole a titre de principes actifs d'une telle composition
CN1235583C (zh) 2001-03-05 2006-01-11 特兰斯泰克制药公司 用作治疗剂的苯并咪唑衍生物
GB0112122D0 (en) * 2001-05-18 2001-07-11 Lilly Co Eli Heteroaryloxy 3-substituted propanamines
CA2464333C (en) 2001-10-26 2011-07-26 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
AU2002347022A1 (en) 2001-12-20 2003-07-09 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
AU2002360819A1 (en) 2001-12-28 2003-07-24 Bayer Corporation Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor
US7244847B2 (en) 2002-02-06 2007-07-17 Isis Pharmaceuticals, Inc. Benzimidazole compounds
CA2478183C (en) * 2002-03-12 2010-02-16 Merck & Co. Inc. Substituted amides
EP1494997A4 (en) * 2002-04-05 2007-04-11 Merck & Co Inc SUBSTITUTED ARYLAMID
JP4459629B2 (ja) * 2002-04-12 2010-04-28 メルク エンド カムパニー インコーポレーテッド 二環式アミド
ATE406363T1 (de) 2003-05-09 2008-09-15 Hoffmann La Roche Methylindole und methylpyrrolopyridine als alpha- 1-adrenerge agonisten
WO2005005439A1 (en) 2003-07-09 2005-01-20 Suven Life Sciences Limited Benzothiazino indoles
EP1663113A4 (en) * 2003-09-18 2007-06-13 Merck & Co Inc SUBSTITUTED SULFONAMIDES
EP1682494A4 (en) * 2003-10-30 2006-11-08 Merck & Co Inc ARALKYLAMINES AS MODULATORS OF CANNABINOID RECEPTORS
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
CN1993321A (zh) * 2004-06-01 2007-07-04 弗·哈夫曼-拉罗切有限公司 作为单胺再摄取抑制剂的3-氨基-1-芳基丙基吲哚类化合物
BRPI0616459A2 (pt) * 2005-09-29 2011-06-21 Wyeth Corp compostos das fórmulas i, ii, e iii; processos para o tratamento ou para a prevenção de: um estado de saúde com melhora devido à recaptação de monoamina; pelo menos um sintoma vasomotor; pelo menos um distúrbio depressivo; pelo menos uma disfunção sexual; para a prevenção de dor; de distúrbio gastrointestinal ou genitourinário; de sìndrome de fadiga crÈnica; de sìndrome de fibromialgia; de esquizofrenia; e uso de um composto

Also Published As

Publication number Publication date
KR101026570B1 (ko) 2011-03-31
KR20080064192A (ko) 2008-07-08
US7638517B2 (en) 2009-12-29
AU2006319233B9 (en) 2011-09-29
JP2009517432A (ja) 2009-04-30
ATE442368T1 (de) 2009-09-15
BRPI0619184A2 (pt) 2011-09-13
CA2632284A1 (en) 2007-06-07
EP1957488A1 (en) 2008-08-20
US20100056499A1 (en) 2010-03-04
ZA200804299B (en) 2009-04-29
TW200804376A (en) 2008-01-16
AR057188A1 (es) 2007-11-21
ES2329413T3 (es) 2009-11-25
WO2007062998A1 (en) 2007-06-07
DE602006009138D1 (de) 2009-10-22
AU2006319233A1 (en) 2007-06-07
CN101321752A (zh) 2008-12-10
RU2008120141A (ru) 2010-01-10
US20070123535A1 (en) 2007-05-31
AU2006319233B2 (en) 2011-06-02
EP1957488B1 (en) 2009-09-09

Similar Documents

Publication Publication Date Title
NO20082112L (no) 3-Amino-2-arylpropylazaindoler og deres anvendelse
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20081844L (no) Terapeutiske forbindelser
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
NO20055496D0 (no) Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
NO20076134L (no) Benzamidderivater og anvendelser derav
NO20063620L (no) Arylanilinderivater som beta2 adrenergiske receptoragonister
NO20064282L (no) Morfolinforbindelser
NO20092033L (no) Nye forbindelser
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
NO20065880L (no) 3-Amino-l-arylpropylindoler som monoamin-gjenopptagelsesinhibitor
TW200833693A (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
ATE512961T1 (de) Amorphes nebivolol hydrochlorid und seine herstellung
NO20091893L (no) Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmater for fremstilling av medisiner inneholdende forbindelsene og anvendelse derav.
NO20074703L (no) Antibakterielle piperidinderivater
NO20064010L (no) Indazolderivater og farmasoytiske preparater inneholdelse slike
DK2054418T3 (da) Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer
TW200639156A (en) New compounds
NO20081942L (no) Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser
NO20082096L (no) Azaindol-2-karboksamidderivativer
NO20076695L (no) Nye MCHR1-antagonister og deres anvendelse for behandling av MCHR1-medierte tilstander og forstyrrelser
NO20062453L (no) Tiozolidinoner, fremstilling og anvendelse derav som legemidler
SE0401342D0 (sv) Therapeutic compounds
MY169274A (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application